RedHill Biopharma (RDHL) Share-based Compensation (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Share-based Compensation data on file, last reported at $1.1 million in Q4 2022.

• On a quarterly basis, Share-based Compensation fell 39.36% year-over-year to $1.1 million in Q4 2022; TTM through Dec 2022 was $5.7 million, a 44.43% decrease from a year earlier, with the FY2025 full-year figure at $457000.0, down 31.28% from the prior year.
• Share-based Compensation for Q4 2022 stood at $1.1 million, down from $1.6 million in the prior quarter.
• Over the last five years, Share-based Compensation for RDHL reached as high as $5.3 million in Q2 2021 and fell as low as $468000.0 in Q3 2018.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $839000.0 in 2018.
• Across the five-year window, Share-based Compensation surged 746.55% in 2021 and tumbled 88.28% in 2022, its largest moves.
• Year by year, Share-based Compensation stood at $671000.0 in 2018, then grew by 11.62% to $749000.0 in 2019, then jumped by 44.46% to $1.1 million in 2020, then soared by 73.29% to $1.9 million in 2021, then plunged by 39.36% to $1.1 million in 2022.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.1 million in Q4 2022, $1.6 million in Q3 2022, and $618000.0 in Q2 2022.